Drugs / BI 1569912
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06520553 | Aug → Oct 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06367153 | May → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04978506 | Sep 2021 → Jul 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04958252 | Aug 2021 → Oct 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04937829 | Jul 2021 → Nov 2023 | major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04445090 | Jul 2020 → Sep 2021 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT06558344 | Oct 2024 → May 2025 | major depressive disorder | Boehringer Ingelheim | Completed | Missed primary |
| Phase 2 | NCT06280235 | Mar 2024 → Feb 2025 | major depressive disorder | Boehringer Ingelheim | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1569912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06520553 ↗ |
| Route | Oral | “single oral dose” NCT04445090 ↗ |